4//SEC Filing
Dolan Daniel 4
Accession 0001104659-22-091490
CIK 0001641640other
Filed
Aug 14, 8:00 PM ET
Accepted
Aug 15, 8:39 PM ET
Size
14.4 KB
Accession
0001104659-22-091490
Insider Transaction Report
Form 4
Dolan Dan
Chief Financial Officer
Transactions
- Exercise/Conversion
Share Options
2022-08-11−83,200→ 0 totalExercise: $0.45Exp: 2032-01-27→ Ordinary Shares (83,200 underlying) - Exercise/Conversion
Restricted Stock Units
2022-08-11−41,600→ 0 total→ Ordinary Shares (41,600 underlying) - Exercise/Conversion
Stock Appreciation Right
2022-08-11+83,200→ 83,200 totalExercise: $0.45Exp: 2032-01-27→ Ordinary Shares (83,200 underlying) - Exercise/Conversion
Phantom Shares
2022-08-11+41,600→ 41,600 total→ Ordinary Shares (41,600 underlying)
Footnotes (4)
- [F1]The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right.
- [F2]Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period.
- [F3]The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares.
- [F4]Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.
Documents
Issuer
Nabriva Therapeutics plc
CIK 0001641640
Entity typeother
Related Parties
1- filerCIK 0001826818
Filing Metadata
- Form type
- 4
- Filed
- Aug 14, 8:00 PM ET
- Accepted
- Aug 15, 8:39 PM ET
- Size
- 14.4 KB